Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Seeks To End Industry’s Use Of Error-Prone Medical Abbreviations

This article was originally published in The Pink Sheet Daily

Executive Summary

In partnership with PhRMA, FDA and the Institute for Safe Medication Practices have launched a campaign to prevent error-prone notation from appearing in labels and advertisements.

You may also be interested in...



Drug Name Mix-Ups Of Aricept/Azilect And Neulasta/Lunesta Under Investigation By FDA

Confusion has occurred with oral and written orders, the Institute for Safe Medication Practices Medication Safety Alert reports.

Drug Name Mix-Ups Of Aricept/Azilect And Neulasta/Lunesta Under Investigation By FDA

Confusion has occurred with oral and written orders, the Institute for Safe Medication Practices Medication Safety Alert reports.

Physician Drug Samples’ Impact On Patient Safety Needs Study, IoM Says

The Institute of Medicine report on medication errors also recommends FDA issue guidances this year on packaging and drug naming.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel